Alunbrig (brigatinib) / Takeda 
Welcome,         Profile    Billing    Logout  
 8 Diseases   24 Trials   24 Trials   1641 News 
37 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alunbrig (brigatinib) / Takeda
2018-003954-26: CYP3A4*22 genotype-guided dosing of TKIs in cancer patients: a new way of personalized therapy Op basis van CYP3A4*22 genotype doseren van tyrosine-kinase remmers bij patiënten met kanker: een nieuwe manier van gepersonaliseerde therapie.

Not yet recruiting
4
198
Europe
Film-coated tablet, Capsule, hard, Coated tablet, Tablet, Cabozantinib/Cabometyx, Cobimetinib/Cotellic, Dabrafenib/Tafinlar, Dasatinib/Sprycel, Erlotinib/Tarceva, Everolimus/Afinitor/Votubia, Imatinib, Lapatinib/Tyverb, Nilotinib/Tasigna, Olaparib/Lynparza, Palbociclib/Ibrance, Ponatinib/Iclusig, Regorafenib/Stivarga, Ruxolitinib/Jakavi, Sunitinib/Sutent, Pazopanib/Votrient, Cabozantinib/Cometriq, Olaparib?Lynparza, Brigatinib - Alunbrig, Encorafenib - Braftovi, Osimertinib/Tagrisso
Erasmus MC Cancer Institute, Erasmus MC
Patients diagnosed with a neoplasm and treated with a tyrosine kinase inhibitor which is mainly metabolised by CYP3A4. Patienten gediagnosticeerd met een maligniteit en behandeld met een tyrosine kinase inhibitor welke voornamelijk wordt gemetaboliseerd door CYP3A4., Patients diagnosed with cancer and treated with a TKI. Patienten gediagnosticeerd met kanker en behandeld met een TKI., Diseases [C] - Cancer [C04]
 
 
ALTA-3, NCT03596866 / 2018-001957-29: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Completed
3
248
Europe, Canada, US, RoW
Brigatinib, Alunbrig, Alectinib, Alecensa
Takeda
ALK+ Advanced NSCLC
02/24
09/24
2019-002230-37: Study of lorlatinib in patients with Lung cancer characterized by a modification of a gene called ALK after after a first line treatment by brigatinib or alectinib

Not yet recruiting
2
112
Europe
lorlatinib, PF6463922, Film-coated tablet, Lorviqua
IFCT, PFIZER, IFCT
advanced ALK-positive non-small cell Lung cancer, advanced lung cancer characterized by a modification of a gene called ALK, Diseases [C] - Cancer [C04]
 
 
2019-001828-36: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Not yet recruiting
2
116
Europe
Brigatinib, Alecensa, Zykadia, Film-coated tablet, Capsule, hard, Alunbrig
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Takeda Pharmaceutical Company Ltd
Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC), Non-small cell lung cancer, Diseases [C] - Cancer [C04]
 
 
2019-002369-36: Utility of analysis in blood of the evolution of the drug brigatinib for patients with lung cancer with ALK mutations Utilidad del análisis en sangre de la evolución del fármaco brigatinib para pacientes con cáncer de pulmón con mutaciones ALK

Not yet recruiting
2
30
Europe
Brigatinib, AP26113, Film-coated tablet, Alunbrig
Fundación GECP, Fundación GECP
ALK+ non-small cell lung cancer Cáncer de pulmón no microcítico ALK+, Lung cancer with ALK mutations in a gen Cáncer de pulmón con mutaciones en el gen ALK, Diseases [C] - Cancer [C04]
 
 
ALTA-2, NCT03535740: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Completed
2
103
Europe, Canada, Japan, US, RoW
Brigatinib, AP26113
Ariad Pharmaceuticals, Takeda
ALK-positive Advanced NSCLC
09/20
08/24
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Recruiting
2
90
RoW
Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel
Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
06/26
08/27
NRG-LU003, NCT03737994: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Active, not recruiting
2
10
US
Alectinib, AF 802, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH 5424802, CH-5424802, CH5424802, RG 7853, RG-7853, RG7853, RO 5424802, RO-5424802, RO5424802, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113, Biganib, Briganix, Trepmac, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ceritinib, LDK 378, LDK-378, LDK378, Zykadia, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Ensartinib, Ensacove, X 396, X-396, X396, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF 06463922, PF-06463922, PF06463922, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
National Cancer Institute (NCI), NRG Oncology
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
07/21
09/25
2021-002567-22: Study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first treatment in patients with advanced ALK-positive lung cancer

Not yet recruiting
2
110
Europe
brigatinib, Film-coated tablet, Concentrate for solution for infusion, Powder for solution for infusion, Alunbrig
IFCT, Takeda, IFCT
Advanced ALK-positive non-small cell lung cancer, Advanced Lung cancer ALK-positive, Diseases [C] - Cancer [C04]
 
 
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
CUBIK, NCT04223596 / 2019-002369-36: Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

Active, not recruiting
2
33
Europe
Brigatinib, AP26113
Fundación GECP, Fundación GECP
Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
12/24
04/25
NCT05361564: A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Not yet recruiting
2
12
RoW
Brigatinib
Yonsei University
Non-small Cell Lung Cancer
06/24
06/24
BRAVES, jRCTs071230025: Phase II Study of Brigatinib for ALK-positive advanced non-small cell lung cancer with brain metastases ( study(LOGIK2201))

Recruiting
2
22
Japan
Alunbrig (brigatinib) - Takeda
Kitasato University Hospital, Takeda Pharmaceutical Co., Ltd
non-small cell lung cancer
 
 
OPTALK, NCT06620835: Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

Not yet recruiting
2
45
Europe
Blood samples for Hematology, Blood samples for Chemistry, Blood sample for liver function tests, Pregnancy test, Tumour assessment, Local Ablative Therapy (LAT)
Groupe Francais De Pneumo-Cancerologie
NSCLC
10/30
10/30
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
BrightStar-2, NCT06522360: Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer

Recruiting
2
168
US
Brigatinib, Alunbrig, Carboplatin, Pemetrexed
M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
12/29
12/31
NCT04074993: Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Active, not recruiting
2
35
RoW
Brigatinib
JI-YOUN HAN, Seoul National University Hospital, Severance Hospital, Seoul National University Bundang Hospital
Non Small Cell Lung Cancer
01/25
03/25
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Active, not recruiting
2
110
Europe
Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, ALK Gene Mutation
04/25
10/28
NCT04318938: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Active, not recruiting
2
118
Europe
Brigatinib, Study treatment, Tyrosine kinase inhibitor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Takeda
NSCLC
01/26
01/26
BOUNCE, NCT05718297: Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Withdrawn
2
44
Europe
Brigatinib, Durvalumab
ETOP IBCSG Partners Foundation, Takeda
NSCLC, Stage III, ALK-rearrangement
09/24
09/24
INTUITT-NF2, NCT04374305: Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis

Active, not recruiting
2
100
US
Brigatinib, Alunbrig, Neratinib, Nerlynx
Scott R. Plotkin, MD, PhD, Takeda, The Children's Tumor Foundation, National Comprehensive Cancer Network
Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
12/29
12/30
2019-004070-26: A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and Expansion Phase in Subjects with Advanced EGFR mutated Non-Small Cell Lung Cancer who are resistant to EGFR tyrosine kinase inhibitors Studio di fase 1/2 che studia la sicurezza, la tollerabilità e l'efficacia di BRIgatinib in combinazione con CEtuximab in pazienti con carcinoma polmonare non a piccole cellule avanzato (NSCLC) con mutazioni di EGFR o positivi per riarrangiamento di ALK o ROS1 e fase di espansione in pazienti con NSCLC EGFR mutati resistenti agli inibitori tirosin-chinasici di EGFR (EGFR-TKI)

Not yet recruiting
1/2
48
Europe
ALUNBRIG, Erbitux, [Brigatinib], [Cetuximab], Film-coated tablet, Solution for infusion, Erbitux
FONDAZIONE RICERCA TRASLAZIONALE (FORT), Takeda Italia S.p.A
Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI); advanced or metastatic ALK or ROS1 positive NSCLC with acquired resistance to specific available inhibitors. carcinoma polmonare non a piccole cellule (NSCLC) avanzato o metastatico positivo per la mutazione del recettore del fattore di crescita epidermico (EGFR) con resistenza acquisita agli inibitori tirosin chinasi della EGFR (TKI) approvati; NSCLC avanzato o metastatico positivo per ALK o ROS1 con resistenza acquisita a specifici inibitori disponibili., Advanced or metastatic epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) with acquired resistance to approved EGFR tyrosine kinase inhibitors (TKI) NSCLC avanzato o metastatico positivo per la mutazione del recettore del fattore di crescita epidermico (EGFR) con resistenza acquisita agli inibitori tirosin chinasi della EGFR (TKI) approvati, Diseases [C] - Cancer [C04]
 
 
Briga-PED, NCT04925609 / 2021-002713-34: Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Recruiting
1/2
65
Europe
Brigatinib, Alunbrig
Princess Maxima Center for Pediatric Oncology, Takeda
Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor
12/29
12/30
NCT06132867: A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Completed
1
12
US
Brigatinib, ALUNBRIG®
Takeda
Healthy Volunteers
02/24
02/24
NCT04227028: Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Active, not recruiting
1
5
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113
City of Hope Medical Center, National Cancer Institute (NCI)
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
06/25
06/25
BRIGHTSTAR, NCT03707938: Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Active, not recruiting
1
35
US
Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113, Local Consolidation Therapy, LCT, Local Consolidative Therapy
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/26
01/26
NCT02784158: An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

No Longer Available
N/A
US
Brigatinib, AP26113
Ariad Pharmaceuticals
Non-small Cell Lung Cancer, Lung Cancer, Advanced Malignancies, Carcinoma
 
 
NCT03389399: Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events with Brigatinib Use in NSCLC and Other Diseases

Active, not recruiting
N/A
18
Canada, US
University of Colorado, Denver, Millennium Pharmaceuticals, Inc., Criterium, Inc.
Non-Small Cell Lung Cancer
10/21
08/25
GALILEO, NCT06234579: Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Recruiting
N/A
108
Europe
Biopsy (tissue or liquid), Alectinib, Brigatinib, Lorlatinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
03/26
07/26
NCT04887519: A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)

Completed
N/A
39
RoW
No Intervention
Takeda
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
03/23
03/23
NCT03546894: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed
N/A
111
US
Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors
Takeda
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
02/23
02/23
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting
N/A
80
Europe
Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
09/26
09/26
Brilliant, NCT05721950: A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

Recruiting
N/A
200
RoW
Brigatinib, Alunbrig
Takeda
Non-small Cell Lung Cancer (NSCLC)
03/25
12/29
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed
N/A
1
Europe
lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib
Pfizer
Non-Small Cell Lung Cancer
01/24
01/24
NCT05100069: Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer

Recruiting
N/A
500
Japan
Brigatinib, Alunbrig Tablets
Takeda
Non-small Cell Lung Cancer (NSCLC)
11/27
11/27
NCT04592523: A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

Recruiting
N/A
257
RoW
No Intervention
Takeda
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
08/26
08/26
ENTIRETY, NCT05735327: A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
N/A
50
Europe
No intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
06/27
06/27

Download Options